Goldman Sachs’s Elevation Oncology ELEV Stock Holding History

Goldman Sachs’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-224,159	Closed	-$82.3K	–	6405
2025 Q2	$82.3K	Buy	224,159 +147,513	+192%	+$49.2K	﹤0.01%	5853
2025 Q1	$19.9K	Sell	76,646 -1,575,077	-95%	-$899K	﹤0.01%	5942
2024 Q4	$929K	Sell	1,651,723 -2,336,749	-59%	-$1.38M	﹤0.01%	4869
2024 Q3	$2.39M	Buy	3,988,472 +3,484,341	+691%	+$5.17M	﹤0.01%	3993
2024 Q2	$1.36M	Sell	504,131 -46,948	-9%	-$177K	﹤0.01%	4238
2024 Q1	$2.83M	Buy	+551,079	New	+$1.79M	﹤0.01%	3592
2023 Q4	–	Sell	-55,878	Closed	-$37K	–	5674
2023 Q3	$37K	Buy	+55,878	New	+$56.5K	﹤0.01%	5307
2022 Q1	–	Sell	-10,294	Closed	-$62K	–	6639
2021 Q4	$62K	Buy	+10,294	New	+$71K	﹤0.01%	6227
2021 Q3	–	Sell	-62,500	Closed	-$848K	–	6299
2021 Q2	$848K	Buy	+62,500	New	+$773K	﹤0.01%	4882

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Goldman Sachs's ELEV Position: Q3 2025 in Review

Goldman Sachs sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 224,159 shares — an estimated $82.3K sold.

Goldman Sachs first reported a position in ELEV in Q2 2021 and held it in 9 quarters. The position peaked at $2.83M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Goldman Sachs reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Goldman Sachs sold 224,159 Elevation Oncology shares in Q3 2025, an estimated $82.3K.
Goldman Sachs first reported a position in Elevation Oncology in Q2 2021 and held it in 9 quarters.
Goldman Sachs's Elevation Oncology position peaked at $2.83M in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.